On May 27, 2022 NEX-I reported that the company selected NXI-101, a new antibody treatment for non-small cell lung cancer that targets immunotherapy-refractory factors (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=15&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643432]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CEO Kyung-wan Yoon"NXI-101Not only does it improve the survival rate of patients who do not respond to existing immunotherapy treatments,,As an anticancer drug that guarantees the patient’s quality of life after treatment, it will bring a new paradigm to the cancer immunotherapy market."said.
The national new drug development project is a domestic pharmaceutical·To strengthen the global competitiveness of the bio industry and secure pharmaceutical sovereignty, which is an essential condition for public health, pharmaceutical companies and academia·kite·Based on bottle open innovation strategy,A pan-ministerial country that supports all stages of new drug developmentR&DStarting this year as a business10years2article2000Investing billions of won.
With the selection of this project, NexI plans to2yearsNXI-101You will receive support for the research costs necessary to derive the lead material.. NXI-101It targets immune evasion factors specifically secreted by cancer cells.First-in-classIt is a new antibody drug..Immune evasion factors are the cause of refractoriness to anticancer immunotherapy.,Controlling this can significantly improve the efficacy of anticancer immunotherapy..
The company said"New drugs under development are derived based on data from a number of immunotherapy-refractory animal models established in-house and from patients who are actually refractory to anti-cancer immunotherapy, so effective clinical efficacy can be expected."He said.
Meanwhile,Nexi this year4It is a new bio venture company established in February..Chief Scientific Officer of Genome & Company(CSO)·CEO Kyung-wan Yoon, who served as vice president,20Through more than a year of research on incurable cancer diseases, many anticancer drugs have been developed.·Professor Kim Tae-woo of Korea University College of Medicine, who has research achievements in immunotherapy, is the Chief Technology Officer.(CTO)I am in charge of.